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Abstract
Objectives: Published human papillomavirus (HPV) vaccine trials indicate efficacy is strongest for those naive to the vaccine-
types. However, few high-risk young women have been followed and cervical HPV has been the predominant outcome
measure.
Methods: We collected cervical and anal swabs, as well as oral rinse specimens from 645 sexually active inner-city young
females attending a large adolescent health-clinic in New York City that offers free care and HPV vaccination. Specimens
were tested for HPV-DNA using a MY09/MY11-PCR system. Type-specific prevalence of HPV at each anatomic site was
compared for individuals by vaccination dose using generalized estimating equation logistic regression models.
Results: The majority of subjects reported being of non-Caucasian (92%) and/or Hispanic ethnicity (61%). Median age was
18 years (range:14–20). All had practiced vaginal sex, a third (33%) practiced anal sex, and most (77%) had also engaged in
oral sex. At enrollment, 21% had not received the vaccine and 51% had received three doses. Prevalent HPV infection at
enrollment was detected in 54% of cervical, 42% of anal and 20% of oral specimens, with vaccine types present in 7%, 6%
and 1% of specimens, respectively. Comparing prevalence for vaccine types, the detection of HPV in the cervix of vaccinated
compared to unvaccinated adolescents was significantly reduced: HPV6/11 (odds ratio [OR]=0.19, 95%CI:0.06–0.75), HPV16
(OR=0.31, 95%CI:0.11–0.88) and HPV18 (OR=0.14, 95%CI:0.03–0.75). For anal HPV, the risk of detecting vaccine types HPV6/
11 (OR=0.27, 95%CI:0.10–0.72) and HPV18(OR=0.12, 95%CI:0.01–1.16) were significantly reduced for vaccinated
adolescents however, the risk for HPV16 was not significantly decreased (OR=0.63, 95%CI:0.18–2.20).
Conclusion: HPV Prevalence is extremely high in inner-city female adolescents. Administration of the HPV vaccine reduced
the risk for cervical HPV; however continued follow-up is required to assess the protection for HPV at all sites in young
women with high exposure.
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Introduction
Cervical human papillomavirus (HPV) infection is the most
common sexually transmitted viral infection (STI). Adolescents
and young women have the highest rates of cervical HPV. The
FDA-approved quadrivalent vaccine, GARDASILH (Merck &
Co.Inc., PA), targets HPV16 and 18 (high-risk types present in
,65% of cervical cancers), as well as HPV6 and 11 (associated
with most genital warts), and has the potential to reduce the
burden of genital HPV and disease. The HPV vaccine clinical
trials, however, focused almost exclusively on low-risk, primarily
non-Hispanic Caucasian women with few sexual partners who
were highly compliant with the vaccine schedule. When women
who had a current infection (i.e., were DNA-positive) with an
HPV vaccine type were assessed, the vaccine was shown to provide
no benefit for preventing future infections by that type [1,2], while
a possible decrease in efficacy was observed among women who
had evidence of prior infection [3,4]. However, the effectiveness of
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37419the vaccine in highly exposed young women has not been
adequately evaluated.
The association of HPV with anal and oropharyngeal papillo-
mas and neoplasia is an important public health concern. Yet few
clinical trials have reported on the effectiveness of the vaccine
against anal or oral HPV [5,6]. Post-marketing surveillance studies
of cervical, anal and oral HPV in real-world settings and high-risk
populations are critically important to evaluate the public health
benefit of HPV vaccination to all segments of the population.
Subsequent to the approval and release of GARDASIL, we
initiated a cohort study of sexually active inner-city, mostly
minority, adolescent females attending the largest adolescent-
specific primary care facility in the U.S. – the Mount Sinai
Adolescent Health Center in New York City; that provides free
health services, including HPV vaccination. The data obtained
from this study will be essential to understanding the real-world
impact of HPV vaccination in high-risk adolescents, and for
determining future cervical cancer prevention and screening
practices in cohorts of women with different HPV vaccine
coverage.
Methods
Objective
In this report, we present data on the prevalence of HPV in this
high-risk population and describe the cross-sectional association
between the detection of cervical, anal and oral HPV with vaccine
exposure.
Study population and setting
The Mount Sinai Adolescent Health Center (MSAHC) uses a
unique model that integrates medical, dental, sexual/reproductive,
mental health and health education services. All services are
confidential and free to patients. It is located on the border of East
Harlem and supports an underserved population of children,
adolescents, and young adults (ages 10–24); ,80% of who are
females, come from all five Boroughs of New York City: 50% from
Central and East Harlem, and other parts of Manhattan, 29%
from the Bronx, and 20% from other Boroughs.
Eligibility criteria
Women are eligible to participate if they: 1) are between 12 and
19 years of age at time of consent, 2) have ever engaged in vaginal
or anal intercourse, and 3) intend to get or have already received
the FDA approved HPV vaccine (GARDASILH). Women
pregnant at time of recruitment or who have terminated a
pregnancy within the last 4 weeks are excluded.
Subject recruitment
Adolescent women presenting to the MSAHC are informed
about the study by research staff. Study flyers are also handed out
instructing women attending the adolescent-health clinic to
contact research staff if they are interested in participating. In
addition, MySpaceH and FacebookH social-networking pages were
created as health education tools to explain facts related to HPV in
more detail (www.myspace.com/hpvinfo; www.facebook.com/
MSAHC).
Ethics
Written informed consent is collected from all participants prior
to enrollment. This study was approved by the Institutional
Review Board at Mount Sinai School of Medicine and the
Committee for Clinical Investigations at Albert Einstein College of
Medicine. Initially, a waiver for parental consent was approved
only for women $18 years of age; this was later extended to
adolescents aged $14 years, and most recently to those 12–13
years of age as per clinic policies.
Clinical history and physical exam
All study participants receive a comprehensive gynecological
examination that includes: sexual, reproductive, behavioral and
psychosocial history, immunization update, blood and urine
testing/screening (as indicated), and anticipatory guidance and
age-specific health education. Screening for Chlamydia, gonor-
rhea and Syphilis is done routinely, and Herpes if symptoms are
present.
Research questionnaires
A self-administered questionnaire consisting of items to assess
risk behaviors for HPV acquisition includes questions on: sexual
behaviors, history of STIs and warts, characteristics of sexual
partners, condom use, use of alcohol and illicit substances for
participants and their sexual partners. The questionnaire is
reviewed by a study coordinator at the time of the visit and any
items not completed are queried. The enrollment clinical interview
and questionnaire data were combined to describe the population
and risk factor profiles for this analysis.
Mucosal specimens for HPV testing
Specimen collection is performed by MSAHC clinicians.
Cervical cells are collected using an endocervical CytobrushH
placed in PreservCyt transport medium (ThinPrepH, Hologic,
MA) medium. Anal cells are also collected in PreservCyt using a
Dacron swab moistened in tap water. Oral cell samples are
collected by oral rinse and gargle using a ScopeH mouthwash
(Proctor&Gamble, OH). Specimens are stored at 220uC imme-
diately following collection. Additional cervical and anal speci-
mens are collected for Pap cytology at enrollment.
HPV DNA genotyping
The polymerase chain reaction (PCR) detection and typing of
HPV-DNA has been described in detail elsewhere [7]. Briefly,
cervical, anal and oral samples are processed in a BioSafety
Cabinet in a laboratory physically separated from where the PCR
amplification is performed. DNA is purified from PreservCyt
material by pelleting the cellular material, digestion with
proteinase-K and Laureth-12, and precipitation with ethanol.
Mouthwash samples are treated with SDS/proteinase-K and the
DNA is phenol/chloroform extracted as described [8]. Five mlo f
purified DNA is then amplified by PCR using Gold-Taq with a
mix of MY09/MY11 L1 consensus primers, which amplifies a
450 bp HPV-DNA fragment, and a control primer set (PC04/
GH20), which simultaneously amplifies a 268 bp cellular beta-
globin DNA fragment as an internal control for amplification
[7,9]. Ten ml of the PCR reaction mix is analyzed by gel
electrophoresis in 3% NuSieve/0.5% SeaKem agarose (FMC
BioProducts,ME), a photo taken of the ethidium stained gel, which
is then transferred to nylon filters (Immobilon, Millipore,MA). The
filters are hybridized overnight with radio-labeled generic probes
for HPV and an oligonucleotide for b-globin as described. The
membranes are washed and exposed to X-ray film (i.e., Southern
blot).
Samples hybridizing to the b-globin probe but negative for the
generic probe are considered HPV negative. PCR products
positive by Southern blot and any sample having a specific DNA
fragment migrating at ,450 bp are analyzed for HPV-DNA type.
Filters are individually hybridized using biotinylated type-specific
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enrollment (N=645).
Cohort characteristics N* (%)
Age at enrollment
14–15 51 (7.9%)
16–17 199 (30.9%)
18–19 395 (61.2%)
Race
Non-Caucasian minority
{ 593 (91.9%)
Ethnicity
Hispanic
{ 392 (60.8%)
Education
10
th or lower 133 (20.6%)
11–12
th grade 252 (39.1%)
High-school graduate/GED 153 (23.7%)
Some college 99 (15.4%)
Sexual activity
Lifetime number of male sexual partners
1 99 (15.4%)
2 104 (16.1%)
3–4 174 (27.0%)
5–9 183 (28.4%)
10–60 85 (13.2%)
Age at first intercourse
10–13 122 (18.9%)
14–15 307 (47.6%)
16–17 187 (29.0%)
18–19 29 (4.5%)
Number of partners in prior 3 months
0 76 (11.8%)
1 416 (64.5%)
2 107 (16.6%)
3–8 46 (7.1%)
Anal intercourse ever
No 431 (66.8%)
Yes 214 (33.2%)
Lifetime number of anal sex partners
1 112 (17.4%)
2+ 48 (7.4%)
Age at first anal intercourse
13–15 33 (5.1%)
16–19 120 (18.6%)
Oral to genital sex
Never 142 (22.0%)
Ever 490 (76.0%)
Oral to anal sex
Never 617 (95.7%)
Ever 15 (2.3%)
Age first gave oral sex (years)
7–15 191 (29.6%)
16–20 308 (47.8%)
Table 1. Cont.
Cohort characteristics N* (%)
Age first received oral sex (years)
7–15 261 (40.5%)
16–19 312 (48.4%)
Vaccine doses received
None (vaccine naı ¨ve) 132 (20.5%)
1 dose 97 (15.0%)
2 doses 89 (13.8%)
3 doses 327 (50.7%)
Interval btw. 1
st sex intercourse and 1
st vaccine
dose
4+ years prior to vaccination 81 (12.6%)
3–4 years prior to vaccination 71 (11.0%)
2–3 years prior to vaccination 82 (12.7%)
1–2 years prior to vaccination 120 (18.6%)
,1 year from date of vaccination 203 (31.5%)
.1 year post vaccination 68 (10.5%)
History of contraceptive use
Withdrawal/Rhythm method 356 (55.2%)
Condom use during vaginal sex
Never 77 (11.9%)
Rarely/Sometimes 228 (35.4%)
Most of the time 201 (31.2%)
Always 129 (20.0%)
Ever use of prescribed contraceptives
{
Oral contraceptive pill 340 (52.7%)
Vaginal ring 164 (25.4%)
Depo-Provera shot 149 (23.1%)
History of pregnancy at entry (N=515)
Ever (including non-full term) 161 (31.3%)
History of sexually transmitted infections
{
Chlamydia 232 (36.0%)
Bacterial vaginosis 174 (27.0%)
Trichomoniasis 49 (7.6%)
Gonorrhea 37 (5.7%)
Genital warts 34 (5.3%)
Cigarette smoking
Never 372 (57.7%)
Yes (no longer) 177 (27.4%)
Yes (current user) 92 (14.3%)
Marijuana smoking
Never 263 (40.8%)
Yes (no longer) 193 (29.9%)
Yes (current user) 178 (27.6%)
Anal Pap (N=600)
Within normal limits 547 (91.2%)
Atypical cells of undetermined significance 48 (8.0%)
Low grade squamous intraepithelial lesions 5 (0.8%)
High grade squamous intraepithelial lesions 0 (0.0%)
Cervical Pap (N=611)
Within normal limits 440 (72.0%)
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HPV 6, 11, 16 and 18. Samples that test positive by the generic
probe mix but negative by all type-specific probes are considered
to represent ‘‘uncharacterized’’ HPV types. Hybridization signals
of the HPV type-specific probes are recorded using a 1–5+
validated scale for signal intensity [10].
Statistical methods
Clinical and demographic characteristics of the study cohort
were examined using frequency distributions. Associations be-
tween risk factors and HPV detection, including vaccine and
related HPV types, were estimated by odds ratios (OR) and 95%
confidence intervals (CI) using multivariable logistic regression. In
addition, to examine the vaccine effect over multiple HPV types,
we fit two models using a previously described generalized
estimating equation (GEE) approach [11]. The first model
compared fully vaccinated subjects (three doses) to unvaccinated
subjects, while the second involved all subjects with the vaccine
doses modeled as an ordinal variable. In both models, the
association between vaccine exposure and detection of HPV 6/11,
16, 18 and non-vaccine HPV types were modeled concurrently
such that the vaccine effect varies by type, and within subject
correlation was adjusted for using an exchangeable correlation
structure. We mutually adjusted for all other significant risk factors
identified by backward elimination, and selected confounders
using a change-in-point estimate criterion for the vaccine effect
[12]. Other (non-vaccine) HPV types detected were assessed
individually and grouped by cancer risk potential, including other
high-risk (HR) types: HPV31, 33, 35, 39, 45, 51, 52, 56, 58, and
59 reported in recent reviews [13,14,15]. Low-risk HPVs included
other non-oncogenic types from the alpha PV genus and
uncharacterized HPV types. Related HR-HPV for vaccine type
16 included HPV31, 33, 35, 52, and 58 (from the alpha-9 genus)
and HPV18-related types 39, 45 and 59 (from the alpha-7 genus).
No HPV6/11-related HPV types (from the alpha-10 genus) were
specifically identified. Statistical analyses were conducted with the
STATA 12.0 and SAS 9.2 statistical software packages.
Results
The cohort consisted of a predominantly minority population
with a median age of 18 years who had not completed high-school
at the time of enrollment (Table 1). Only eight percent of subjects
identified themselves as Caucasian. All subjects reported vaginal
intercourse, some (33.2%) reported anal intercourse, and most
(76.6%) also had oral-to-genital or oral-to-anal sex. The majority
of subjects (68.5%) had had at least three sexual partners in their
lifetime, and 41.6% had five or more partners. The overall median
age at first vaginal intercourse was 15 years (range:10–19).
Participants who enrolled before the age of 16, however, had a
median age at first intercourse of 14 years. Over half of the
subjects (54.9%) had initiated sexual intercourse a year or more
before vaccination.
History of STIs in the population was high including Chlamydia
(36.0%), trichomoniasis (7.6%), gonorrhea (5.7%), and genital
warts (5.3%). Almost half (47.3%) of adolescents reported using
condoms ‘never’, ‘rarely’ or only ‘sometimes’ when practicing
vaginal sex, and many (55.2%) also reported using the withdrawal
or rhythm method for contraception. The majority of adolescents,
however, used some form of recurrent prescription-based contra-
ception including oral contraceptive pills (52.7%), vaginal rings
(25.4%) or Depo-Provera injections (23.1%). More than a quarter
(31.3%) of subjects reported having been pregnant.
HPV type-specific prevalence
Overall HPV-DNA detection at enrollment was 53.5% in the
cervix, 41.5% in the anal canal, and 19.6% in the oral cavity. The
prevalence of at least one vaccine type (i.e., HPV6/11/16/18) was
6.6%, 6.2% and 1.3% in the cervical, anal and/or oral specimens,
respectively. Among the most commonly detected cervical HPV
types (i.e., .5% type-specific prevalence) were HR-HPV types
HPV51 and 58, as well as low-risk types 53, 66, 84 and 90/106
(Figure 1). The most common HPV types in the cervix were often
also the most common types detected in the anal canal (including
HPV51, 53, 58, 84 and 90/106, which were detected in .3% of
specimens). Nevertheless, the type-specific cervical and anal
concordance within individuals for these types was variable (range
for non-vaccine HR-HPV types: 8.3%–42.4% and 25.0%–40.0%
for vaccine types). Combined, the prevalence of HR-HPV types
excluding HPV16/18 in the cervix was 27.9%, while detection
levels of HR-HPV types in the anal canal and oral cavity were
17.9% and 1.9%, respectively. Co-infection with vaccine types 16
or 18 in the cervix was found in 13.9% (N=26/187) of HR-HPV
positive subjects, and corresponding co-infection rates in the anal
canal and oral cavity were 18% and 25%, respectively.
Risk factors for cervical and anal HPV detection
We examined the risk factors for HPV-vaccine, vaccine-related
HR-types and all HPV types in the cervix or anal canal, using
logistic regression adjusting only for vaccine dose (Table 2).
Significant associations were observed for detection of any HPV in
the cervix with increasing lifetime and recent number of male
vaginal sex partners, anal intercourse, oral to anal sex, use of
Depo-Provera injections and history of Chlamydia. Detection of
anal HPV was also associated with higher lifetime and recent
number of anal and vaginal sex partners, younger age at first anal
intercourse, and history of Chlamydia and anogenital warts. No
statistically significant risk associations were observed with oral
HPV (not shown) due to small numbers of positive cases.
Except for vaccine exposure, similar risk factor associations were
observed for detection of vaccine types alone and related HR-
HPV (alpha-9 and -7) types. Whereas vaccine types were
significantly less likely to be detected in the cervix and anal canal
with any vaccine exposure, this was not observed for other related
HR-HPV types or all types combined. Subjects who had engaged
in vaginal sex more than two years prior to vaccination were also
more likely to present with an HPV infection independent of
vaccine dose.
Table 1. Cont.
Cohort characteristics N* (%)
Atypical cells of undetermined significance 109 (17.8%)
Low grade squamous intraepithelial lesions 61 (10.0%)
High grade squamous intraepithelial lesions 1 (0.2%)
*Category totals may not add up to 645 due to missing data.
{Includes African-American, Native American, Pacific or Caribbean island, and
Asian descent. Race and ethnicity are overlapping.
{Subjects may have acquired more than one STI or used more than one
contraceptive method.
doi:10.1371/journal.pone.0037419.t001
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At enrollment, 20.5% of subjects had yet to receive the HPV
vaccine, 15.0% had received their first dose, 13.8% a second dose,
and 50.7% all three doses. Comparing prevalence for HPV
vaccine types among adolescents entering the study with all three
vaccine doses compared to unvaccinated subjects, we observed
significantly lower HPV6/11 detection for fully vaccinated
compared to unvaccinated subjects in the cervix (OR=0.21,
Fisher’s exact test p=0.005), anal canal (OR=0.30, p=0.013),
and oral cavity (OR<0.08, p=0.081; Figure 2). Gradual declines
in HPV6/11 prevalence were also found with increasing dose from
none to three doses for the cervix (Wilcoxon rank sum test p for
trend=0.004) and anal canal (p-trend=0.009). With respect to
HR-HPV vaccine types 16 and 18, we observed a significantly
lower prevalence with vaccination in the cervix (OR=0.34,
p=0.042, p-trend=0.074; and OR=0.16, p=0.023, p-
trend=0.022, respectively). In contrast, whereas the decline in
anal HPV18 was significant (OR=0.13, p=0.073, p-
trend=0.033), the decrease in anal HPV16 was not (OR=0.69,
p=0.519, p-trend=0.924). Detection of HPV16 and 18 in the
oral cavity was low overall and non-existent among subjects with
one or two vaccine doses. Nonetheless, these cross-sectional data
raise the possibility that HPV vaccination might have less impact
on extra-cervical HR-HPV types when administered to a sexually
active high-risk population. These associations, however, were not
adjusted for sexual activity or other concurrent HPV type
infections. To address this, we performed a GEE multivariable
logistic regression analysis.
Table 3 shows the relative risk associations estimated by OR
for HPV detection by vaccine exposure mutually adjusting for
concurrent HPV types, as well as other epidemiological risk factors
and confounders. We observed statistically significant risk reduc-
tions in detecting HPV types 16, 6/11 and 18 in the cervix of 69%,
81% and 86%, respectively, among adolescents who had three
doses compared to those who had no vaccination. However, a
statistically non-significant 37% risk reduction for detecting
HPV16 in the anal canal was observed amongst fully vaccinated
adolescents compared to non-vaccinated adolescents (OR=0.63,
95%CI:0.18–2.20), whereas significant reductions of 73% and
88% were seen for HPV6/11 and HPV18, respectively. When
vaccine exposure was modeled by dose (including subjects with
only one or two doses at enrollment), we found that the odds of
detecting HPV6/11 per vaccine dose were significantly lower for
the cervix (ORdose=0.54, 95%CI:-.36–0.83) and anal canal
(ORdose=0.61, 95%CI:0.43–0.86), as well for HPV18 in the anal
canal (ORdose=0.46, 95%CI:0.23–0.93).
Independent of HPV16 and 18, the adjusted OR for detecting
other HR-HPV types combined did not show significance. We
further assessed the type-specific prevalence for vaccine related
HR-HPV types from within the alpha-9 and -7 genera by vaccine
exposure (Figure 3). Significant declines in detection were
Figure 1. HPV type distribution at enrollment among all adolescents. Key: * Any high-risk (HR) HPV type excluding HPV16/18. { Any low-risk
(LR) HPV type excluding HPV6/11.
doi:10.1371/journal.pone.0037419.g001
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Cervical HPV Anal HPV
Characteristics
Vaccine types
(6/11/16/18)
Related
HR-types All types
Vaccine types
(6/11/16/18)
Related
HR-types All types
Age at entry
14–15 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
16–17 3.0 0.4–24.5 1.9 0.8–4.5 1.5 0.8–2.7 2.9 0.4–23.3 1.6 0.6–4.3 1.1 0.6–2.1
18–20 4.4 0.6–33.7 1.5 0.7–3.6 1.4 0.8–2.5 3.9 0.5–29.8 1.2 0.4–3.1 1.3 0.7–2.3
Ethnicity
Non-Hispanic 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Hispanic 0.8 0.4–1.4 1.0 0.6–1.4 0.8 0.6–1.1 0.7 0.3–1.3 1.0 0.6–1.7 0.8 0.5–1.0
Sexual activity
Lifetime # of male vaginal sex partners
1 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
2 1.4 0.4–5.3 1.4 0.6–3.0 2.1 1.2–3.7 0.7 0.1–4.0 0.6 0.2–1.9 1.0 0.5–1.8
3–4 2.0 0.6–6.8 2.0 1.0–3.9 3.7 2.1–6.3 2.4 0.7–9.1 2.1 0.9–4.9 2.0 1.2–3.4
5+ 2.4 0.8–7.4 2.1 1.0–3.9 4.0 2.4–6.6 3.4 1.0–11.6 1.8 0.8–4.0 2.1 1.3–3.5
Age at first vaginal intercourse
16+ 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
14–15 1.0 0.5–2.1 1.2 0.8–1.8 1.0 0.7–1.4 1.7 0.8–3.9 1.4 0.8–2.6 0.9 0.6–1.2
,14 1.4 0.6–3.4 0.8 0.4–1.5 1.1 0.7–1.7 2.0 0.8–5.3 2.1 1.1–4.1 1.0 0.7–1.6
Number of partners (prior 3 months)
0 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
1 0.6 0.2–1.5 0.9 0.5–1.7 1.0 0.6–1.6 1.2 0.4–3.6 0.8 0.4–1.7 1.4 0.8–2.5
2+ 1.6 0.6–4.2 1.3 0.6–2.5 2.2 1.2–3.9 2.0 0.6–6.4 0.9 0.4–2.1 1.8 1.0–3.3
Anal intercourse ever
No 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Yes 1.2 0.6–2.2 1.2 0.8–1.9 1.5 1.1–2.1 2.0 1.0–3.9 1.9 1.2–3.1 1.5 1.0–2.1
Lifetime number of anal sex partners
0 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
1 1.1 0.5–2.4 1.0 0.6–1.7 1.6 1.0–2.4 1.2 0.5–2.9 1.0 0.5–1.9 1.1 0.7–1.7
2+ 0.6 0.1–2.9 1.2 0.6–2.4 1.1 0.6–1.9 2.8 1.1–7.4 2.9 1.4–6.0 1.6 0.9–3.0
Age at first anal intercourse
Never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
16+ 1.1 0.5–2.5 1.0 0.6–1.7 1.3 0.8–1.9 1.3 0.5–2.9 1.2 0.6–2.3 1.0 0.7–1.7
,16 0.9 0.2–4.2 1.3 0.6–2.9 1.9 0.9–4.1 3.2 1.1–9.2 4.5 2.0–9.9 2.4 1.2–5.1
Oral to genital sex
Never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Ever 1.3 0.6–3.0 1.0 0.6–1.5 1.0 0.7–1.5 1.3 0.6–3.1 1.2 0.7–2.3 1.2 0.8–1.8
Oral to anal sex
Never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Ever 4.2 1.3–13.7 4.6 1.6–13.5 5.4 1.2–24.8 3.6 1.0–13.0 2.5 0.7–8.4 2.6 0.9–8.1
Age first gave oral sex
Never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
16+ 1.9 0.7–5.1 1.3 0.7–2.3 1.4 0.9–2.2 1.8 0.6–6.0 1.2 0.6–2.4 1.3 0.8–2.0
,16 1.7 0.7–4.3 1.4 0.8–2.4 1.3 0.9–2.0 2.9 1.0–8.4 0.9 0.5–1.8 1.3 0.8–1.9
Age first received oral sex
Never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
16+ 1.6 0.4–5.7 1.2 0.6–2.4 1.2 0.7–2.0 1.6 0.4–5.5 1.2 0.5–2.7 1.3 0.7–2.3
,16 1.3 0.4–4.7 1.3 0.7–2.6 1.3 0.8–2.1 1.3 0.4–4.7 1.0 0.4–2.2 1.4 0.8–2.5
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p-trend=0.018) and HPV16-related type 31 (OR=0.39,
95%CI:0.1–1.2, p-trend=0.027) in the cervix, and in the anal
canal (OR=0.0, 95%CI:0.0–0.8, p-trend=0.027; and OR=0.19,
95%CI:0.1–0.7, p-trend=0.009, respectively). Similar declines,
albeit not significant, were observed at both sites only for HPV59.
Furthermore, although not significant, an increased prevalence of
cervical HPV35, 52 and 58 was seen in vaccinated individuals;
similar increases were recently reported for vaccinated individuals
in two studies [16,17].
Discussion
The HPV quadrivalent vaccine has been shown to have high
efficacy against infection as well as HPV16/18-positive cervical
pre-cancer and HPV6/11-positive genital warts [2,18]. However,
the vaccine trials focused exclusively on low risk, mostly non-
Hispanic Caucasian women with few (no more than four) sexual
partners, who had no history of abnormal cervical cytology,
cervical disease or genital warts, and who were highly compliant
with the vaccine schedule [2,18,19,20]. In this article, we assessed
the HPV burden in a high-risk urban minority adolescent female
population, and describe the cross-sectional association between
the detection of cervical and extra-cervical HPV with vaccine
exposure. The cross-sectional data shown here indicates that there
is continued detection of cervical HPV with vaccine types after
vaccination. This raises questions regarding the ‘real-world’
impact of vaccinating high-risk populations (unlike those studied
in the vaccine trials) with potentially frequent prior exposures to
vaccine types as well as to other HR-HPV types. Moreover,
Table 2. Cont.
Cervical HPV Anal HPV
Characteristics
Vaccine types
(6/11/16/18)
Related
HR-types All types
Vaccine types
(6/11/16/18)
Related
HR-types All types
Vaccine doses received
{
None (vaccine naı ¨ve) 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
3 doses 0.2 0.1–0.4 0.8 0.5–1.3 0.7 0.4–1.0 0.3 0.2–0.7 0.7 0.4–1.3 0.7 0.5–1.0
Interval btw 1
st sex and vaccination
2+ years prior to vaccination 2.4 0.5–11.3 1.2 0.6–2.7 1.9 1.0–3.4 6.8 0.9–54.4 1.7 0.5–5.3 1.1 0.6–2.0
1–2 years prior to vaccination 0.6 0.1–3.7 1.2 0.5–2.7 1.4 0.8–2.6 2.2 0.2–20.9 1.7 0.5–5.7 0.9 0.5–1.6
Within 1 year of vaccination 1.1 0.2–5.5 1.4 0.7–3.0 1.4 0.8–2.5 2.0 0.2–17.2 2.6 0.9–7.7 1.1 0.6–2.0
.1 year post vaccination 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Prescribed contraceptives
Depo-Provera shot never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Depo-Provera shot ever 1.5 0.7–3.1 1.5 1.0–2.4 1.5 1.0–2.2 1.6 0.8–3.4 1.9 1.1–3.2 1.2 0.8–1.8
History of STI
Chlamydia never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Chlamydia ever 2.5 1.3–4.9 1.1 0.7–1.7 2.2 1.6–3.1 2.2 1.1–4.3 1.7 1.1–2.8 2.2 1.6–3.1
Genital warts never 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 -
Genital warts ever 2.9 1.1–7.7 1.2 0.5–2.7 1.9 0.9–3.9 5.4 2.2–13.1 1.0 0.3–3.0 3.0 1.4–6.4
*Odds ratio (OR) and 95% confidence intervals (CI) shown were derived by logistic regression adjusting for vaccine status only.
{Due to small numbers, estimates are only shown for the comparison between fully vaccinated to unvaccinated subjects, excluding those entering study with 1 or 2 doses.
doi:10.1371/journal.pone.0037419.t002
Table 3. Adjusted associations with vaccine exposure for detecting a type-specific HPV infection.
HPV types Cervical HPV Anal HPV
OR 3 doses (95%CI)* p-value* OR 3 doses (95%CI)* p-value*
HPV6/11 0.19 (0.06–0.59) 0.004 0.27 (0.10–0.72) 0.009
Other low-risk types excluding
HPV6/11
0.56 (0.36–0.85) 0.007 0.84 (0.52–1.35) 0.470
HPV16 0.31 (0.11–0.88) 0.028 0.63 (0.18–2.20) 0.469
HPV18 0.14 (0.03–0.75) 0.022 0.12 (0.01–1.16) 0.067
Other high-risk types excluding
HPV16/18
0.76 (0.47–1.22) 0.254 0.65 (0.39–1.11) 0.115
*Odds ratios (OR), 95% confidence intervals (CI) and p-values are shown for vaccine effect on HPV detection for each HPV type (or types) comparing fully vaccinated to
unvaccinated subjects excluding those presenting with 1 or 2 doses at enrollment. The estimates were derived by multivariate generalized estimating equation (GEE) with
logistic regression mutually adjusting for all concurrent types, age, ethnicity, number of vaginal sex partners, and history of chlamydia.
doi:10.1371/journal.pone.0037419.t003
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women, we also observe a high prevalence of extra-cervical HPV
among both vaccinated and unvaccinated individuals. These
observations have important public health implications for future
screening and prevention of HPV-related cancer in a high-risk
population.
The reported study has strengths and limitations. The current
study evaluated HPV at multiple anatomical sites associated with
sexual exposure. While it is generally understood that acquisition
and prevalence of cervical HPV is at its highest in adolescent
women, how this relates to the prevalence and acquisition of HPV
in other tissues susceptible to HR-HPV associated tumorigenesis
(i.e., the anal epithelium and oral cavity), is not currently known.
Among the limitations, it should be noted that because we are
specifically targeting sexually active adolescent females, either at
the time they receive the HPV vaccine or soon thereafter, our
population is older than the targeted age for vaccination, but
covers the age range recommended for catch-up vaccination
(www.cdc.gov/std/hpv/STDFact-HPV-vaccine-hcp.htm). In ad-
dition, we assessed cross-sectional associations between HPV-DNA
infection, vaccine exposure and risk factors. As such, the history of
HPV exposure prior to vaccination is not known for those
individuals enrolled after vaccine initiation. Furthermore, it is
impossible to ascertain via HPV-DNA detection alone if test
positivity is equated with true (active, albeit latent) viral infection
that may cause neoplastic disease. With longitudinal follow-up, we
will be able to assess the HPV incidence and risk factors for
‘‘breakthrough’’ persistent infections (i.e., repeated detection of an
HPV vaccine type in someone who was previously HPV-DNA
negative for that type at enrollment) [21].
When compared to the general MSAHC clinic population (data
not shown), the study cohort is younger (mean patient age in 2010
was 18.6 vs. 17.7 in this study) but comparable in terms of prior
STIs. The high-risk nature of the population is also evident in the
observed prevalent HPV detection. Among the strongest risk
factors for detection of cervical and anal HPV (independent of
vaccination) were number of sexual partners, anal intercourse,
oral-to-anal sex, receipt of a Depo-Provera injection, and history
of Chlamydia. Vaccination was significantly associated with
cervical and anal HPV detection only after the vaccine types
were assessed separately.
Recent evidence suggests the HPV vaccines will impact both
cervical and anal HPV co-incidence rates, although efficacy
against anal HPV depends on cervical HPV positivity [5,6,22].
Interestingly, whereas detection of anal HPV vaccine types 6/11
and 18 were significantly lower among vaccinated individuals in
this study, the corresponding decrease for HPV16 was not. This
was independent of the presence of other HPV types, prior sexual
activity and other risk factors. A lower efficacy was observed
against persistent anal infection by HPV16 (54.0%) compared to
HPV18 (73.6%) in the quadrivalent HPV vaccine male trial
intent-to-treat analyses [5]. Lower efficacy rates have also been
reported in women against anal HPV16 and 18 infections (68.2%
and 55.5%, respectively) compared to the cervix (75.8% and
Figure 2. Site specific prevalence of HPV vaccine types by vaccine exposure. Key: HPV types showing significant differences (by Fisher’s
exact test p,0.1) are indicated by starred brackets.
doi:10.1371/journal.pone.0037419.g002
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particular has been shown to be associated with the majority of
anal and oropharyngeal neoplasias. The implications of HPV
infection at non-cervical sites on vaccine efficacy, however, remain
to be evaluated. Moreover, while testing for HPV is approved as
an adjunct screening test to Pap cytology for the cervix, testing of
other sites (anal or oral) is not routinely performed.
Finally, whereas the odds of detecting HPV vaccine types in the
cervix decreased significantly among vaccinated adolescents, the
odds of detecting other vaccine related and un-related HR-HPV
types did not show consistent decreases with vaccination. We
Figure 3. Site specific prevalence of HPV vaccine-related types by vaccine exposure. Key: HPV types showing significant differences (by
Fisher’s exact test p,0.1) are indicated by starred brackets.
doi:10.1371/journal.pone.0037419.g003
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HPV16 and 18-related HR-HPV types 31 and 45 in the cervix
and anal canal, respectively, as did other studies. While history of
previous infection with a vaccine type could not be controlled for
in the analyses, it is unlikely the result is solely due to prior
exposure given the observed prevalence among unvaccinated
individuals. Vaccine efficacy has been shown against persistent
infection in the trial cohorts for HPV33, 31, 45 and 51 (with or
without HPV16/18 co-infection) [16,17]. The detection of other
common HR-HPV types in vaccinated populations that will
remain at a high risk of disease has implications for future
preventative and screening strategies.
In summary, our data to date suggest continued detection of
cervical and extra-cervical infection with HPV vaccine types after
vaccination, in addition to other HR-HPV types. This study
provides the ‘real-world’ impact of vaccinating high-risk adoles-
cent populations (unlike those studied in the vaccine trials) with
potentially frequent prior exposures to HPV vaccine types, as well
as to related HR-HPV types. Findings from studies such as this are
therefore critical to document the continued burden of HPV and
to properly design future multi-type prophylactic HPV vaccines
and continued screening strategies to prevent HPV-related disease.
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